Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016-2019.

Disease burden Epidemiology Hospitalization Mortality Respiratory syncytial virus

Journal

Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499

Informations de publication

Date de publication:
06 Feb 2024
Historique:
received: 02 11 2023
accepted: 10 01 2024
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: aheadofprint

Résumé

Respiratory syncytial virus (RSV) causes a substantial disease burden among infants. In older children and adults, incidence is underestimated due to nonspecific symptoms and limited standard-of-care testing. We aimed to estimate RSV-attributable hospitalizations and deaths in Spain during 2016-2019. Nationally representative hospitalization and mortality databases were obtained from the Ministry of Health and the National Statistical Office. A quasi-Poisson regression model was fitted to estimate the number of hospitalizations and deaths attributable to RSV as a function of periodic and aperiodic time trends and viral activity, while allowing for potential overdispersion. In children, the RSV-attributable respiratory hospitalization incidence was highest among infants aged 0-5 months (3998-5453 cases/100,000 person-years, representing 72% of all respiratory hospitalizations) and decreased with age. In 2019, estimated rates in children 0-5, 6-11, 12-23 months and 6-17 years were approximately 1.3, 1.4, 1.5, and 6.5 times higher than those based on standard-of-care RSV-specific codes. In adults, the RSV-attributable cardiorespiratory hospitalization rate increased with age and was highest among persons ≥ 80 years (1325-1506 cases/100,000, 6.5% of all cardiorespiratory hospitalizations). In 2019, for persons aged 18-49, 50-59, 60-79, and ≥ 80 years, estimated rates were approximately 8, 6, 8, and 16 times higher than those based on standard-of-care RSV-specific codes. The RSV-attributable cardiorespiratory mortality rate was highest among ≥ 80 age group (126-150 deaths/100,000, 3.5-4.1% of all cardiorespiratory deaths), when reported mortality rate ranged between 0 and 0.5/100,000. When accounting for under-ascertainment, estimated RSV-attributable hospitalizations were higher than those reported based on standard-of-care RSV-specific codes in all age groups but particularly among older children and older adults. Like other respiratory viruses, RSV contributes to both respiratory and cardiovascular complications. Efficacious RSV vaccines could have a high public health impact in these age and risk groups.

Identifiants

pubmed: 38319540
doi: 10.1007/s40121-024-00920-7
pii: 10.1007/s40121-024-00920-7
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

© 2024. Pfizer Inc.

Références

Chadha M, Hirve S, Bancej C, Barr I, Baumeister E, Caetano B, et al. Human respiratory syncytial virus and influenza seasonality patterns-early findings from the WHO global respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):638–46.
pubmed: 32163226 pmcid: 7578323 doi: 10.1111/irv.12726
Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–69.
pubmed: 27740723 doi: 10.1002/ppul.23570
Nguyen-Van-Tam JS, O’Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166):220105.
pubmed: 36384703 pmcid: 9724807 doi: 10.1183/16000617.0105-2022
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.
pubmed: 35598608 pmcid: 7613574 doi: 10.1016/S0140-6736(22)00478-0
Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther. 2023;12(4):1137–49.
pubmed: 36941483 pmcid: 10027261 doi: 10.1007/s40121-023-00792-3
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759.
pubmed: 36175846 pmcid: 9520861 doi: 10.1186/s12879-022-07745-0
Heppe-Montero M, Gil-Prieto R, Del Diego SJ, Hernández-Barrera V, Gil-de-Miguel Á. Impact of respiratory syncytial virus and influenza virus infection in the adult population in Spain between 2012 and 2020. Int J Environ Res Public Health. 2022;19(22):14680.
pubmed: 36429399 pmcid: 9690810 doi: 10.3390/ijerph192214680
Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Infect Dis Ther. 2023;12(2):677–85.
pubmed: 36707466 pmcid: 9883084 doi: 10.1007/s40121-023-00758-5
Datta S, Walsh EE, Peterson DR, Falsey AR. Can analysis of routine viral testing provide accurate estimates of respiratory syncytial virus disease burden in adults? J Infect Dis. 2017;215(11):1706–10.
pubmed: 28863444 doi: 10.1093/infdis/jix196
Muscatello DJ, Amin J, MacIntyre CR, Newall AT, Rawlinson WD, Sintchenko V, et al. Inaccurate ascertainment of morbidity and mortality due to influenza in administrative databases: a population-based record linkage study. PLoS ONE. 2014;9(5): e98446.
pubmed: 24875306 pmcid: 4038604 doi: 10.1371/journal.pone.0098446
Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443.
pubmed: 26497750 pmcid: 4618996 doi: 10.1186/s12879-015-1218-z
Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–9.
pubmed: 25851217 doi: 10.1007/s40266-015-0258-9
Lee N, Walsh EE, Sander I, Stolper R, Zakar J, Wyffels V, et al. Delayed diagnosis of respiratory syncytial virus infections in hospitalized adults: individual patient data, record review analysis and physician survey in the United States. J Infect Dis. 2019;220(6):969–79.
pubmed: 31070757 pmcid: 6688061 doi: 10.1093/infdis/jiz236
Talbot HK, Belongia EA, Walsh EE, Schaffner W. Respiratory syncytial virus in older adults. A hidden annual epidemic. Infect Dis Clin Pract. 2016;24(6):295–302.
doi: 10.1097/IPC.0000000000000455
Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738–49.
pubmed: 26354816 pmcid: 4652120 doi: 10.1128/JCM.01816-15
Onwuchekwa C, Atwell J, Moreo LM, Menon S, Machado B, Siapka M, et al. Pediatric RSV diagnostic testing performance: a systematic review and meta-analysis. J Infect Dis. 2023;228:1516–27.
pubmed: 37285396 pmcid: 10681870 doi: 10.1093/infdis/jiad185
Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al. Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR. Infect Dis Ther. 2023;12(6):1593–603.
pubmed: 37148463 pmcid: 10163290 doi: 10.1007/s40121-023-00805-1
Kujawski SA, Whitaker M, Ritchey MD, Reingold AL, Chai SJ, Anderson EJ, et al. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure-United States, 2015–2017. PLoS ONE. 2022;17(3): e0264890.
pubmed: 35263382 pmcid: 8906631 doi: 10.1371/journal.pone.0264890
Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574–83.
pubmed: 29622165 doi: 10.1016/j.jacc.2018.02.013
Franczuk P, Tkaczyszyn M, Kulak M, Domenico E, Ponikowski P, Jankowska EA. Cardiovascular complications of viral respiratory infections and COVID-19. Biomedicines. 2022. https://doi.org/10.3390/biomedicines11010071 .
doi: 10.3390/biomedicines11010071 pubmed: 36672579 pmcid: 9856218
Schanzer DL, Langley JM, Tam TW. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respir Viruses. 2008;2(1):1–8.
pubmed: 19453488 pmcid: 4634329 doi: 10.1111/j.1750-2659.2008.00035.x
Matias G, Taylor RJ, Haguinet F, Schuck-Paim C, Lustig RL, Shinde V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status. BMC Public Health. 2017;17(1):271.
pubmed: 28320361 pmcid: 5359836 doi: 10.1186/s12889-017-4177-z
Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis. 2012;54(10):1427–36.
pubmed: 22495079 pmcid: 3334364 doi: 10.1093/cid/cis211
Muller-Pebody B, Crowcroft NS, Zambon MC, Edmunds WJ. Modelling hospital admissions for lower respiratory tract infections in the elderly in England. Epidemiol Infect. 2006;134(6):1150–7.
pubmed: 16729903 pmcid: 2870521 doi: 10.1017/S0950268806006376
Matias G, Taylor RJ, Haguinet F, Schuck-Paim C, Lustig RL, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997–2009 by influenza type or subtype, age, cause of death, and risk status. Influenza Other Respir Viruses. 2014;8(5):507–15.
pubmed: 24975705 pmcid: 4181813 doi: 10.1111/irv.12258
Hardelid P, Pebody RG, Andrews N. Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999–2010. Influenza Other Respir Viruses. 2013;7(1):35–45.
pubmed: 22405488 doi: 10.1111/j.1750-2659.2012.00345.x
Griffin MR, Coffey CS, Neuzil KM, Mitchel EF Jr, Wright PF, Edwards KM. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med. 2002;162(11):1229–36.
pubmed: 12038940 doi: 10.1001/archinte.162.11.1229
Goldstein E, Greene SK, Olson DR, Hanage WP, Lipsitch M. Estimating the hospitalization burden associated with influenza and respiratory syncytial virus in New York City, 2003–2011. Influenza Other Respir Viruses. 2015;9(5):225–33.
pubmed: 25980600 pmcid: 4548992 doi: 10.1111/irv.12325
Zheng Z, Warren JL, Shapiro ED, Pitzer VE, Weinberger DM. Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups. Pneumonia (Nathan). 2022;14(1):6.
pubmed: 36280891 doi: 10.1186/s41479-022-00098-x
Mullooly J, Bridges C, Thompson W, Chen J, Weintraub E, Jackson L, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25(5):846–55.
pubmed: 17074423 doi: 10.1016/j.vaccine.2006.09.041
Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179–86.
pubmed: 12517228 doi: 10.1001/jama.289.2.179
Karstaedt AS. Influenza- and respiratory syncytial virus-associated adult mortality in Soweto. S Afr Med J. 2009;99(10):750–4.
pubmed: 20128275
Nazareno AL, Muscatello DJ, Turner RM, Wood JG, Moore HC, Newall AT. Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009–2017. Influenza Other Respir Viruses. 2022;16(6):1082–90.
pubmed: 35775106 pmcid: 9530581 doi: 10.1111/irv.13003
McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300.
pubmed: 35873302 pmcid: 9301578 doi: 10.1093/ofid/ofac300
Registro de Actividad de Atención Especializada. RAE-CMBD 2022 Ministerio de Sanidad; 2022. https://www.sanidad.gob.es/estadEstudios/estadisticas/cmbdhome.htm .
Quirós-González V, Bernal JL, Haro-Pérez AM, Maderuelo-Fernández JA, Santos-Jiménez MT, García-Barrio N, et al. Validity and usefulness of the RAE-CMBD studying patients hospitalised with influenza. Rev Esp Quimioter. 2023;36(2):160–8.
pubmed: 36651282 pmcid: 10066910 doi: 10.37201/req/074.2022
Rodríguez del Águila M P-ME, Librero J, BuzónBarrera M, Rivas Ruiz Atlas VPM Nº 4. Análisis del control de calidad del Conjunto Mínimo de Datos Básicos de Andalucía en los años 2000 a 2003. Sevilla, 2004.
Instituto Nacional de Estadística. Base de datos de mortalidad, Base de datos de mortalidad (Demografía y población/Fenómenos demográficos/Tablas de mortalidad), 2022. Available from: https://www.ine.es .
WHO. International statistical classification of diseases and related health problems. 10th ed. World Health Organization; 2016.
Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection–a systematic review. Crit Care. 2006;10(4):R107.
pubmed: 16859512 pmcid: 1751022 doi: 10.1186/cc4984
Kawashima H, Inagaki N, Nakayama T, Morichi S, Nishimata S, Yamanaka G, et al. Cardiac complications caused by respiratory syncytial virus infection: questionnaire survey and a literature review. Glob Pediatr Health. 2021. https://doi.org/10.1177/2333794X211044114 .
doi: 10.1177/2333794X211044114 pubmed: 34527765 pmcid: 8436282
Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83–92.
pubmed: 20113977 doi: 10.1016/S1473-3099(09)70331-7
Schanzer DL, Saboui M, Lee L, Nwosu A, Bancej C. Burden of influenza, respiratory syncytial virus, and other respiratory viruses and the completeness of respiratory viral identification among respiratory inpatients, Canada, 2003–2014. Influenza Other Respir Viruses. 2018;12(1):113–21.
pubmed: 29243369 doi: 10.1111/irv.12497
Calvo C, Pozo F, García-García ML, Sanchez M, Lopez-Valero M, Pérez-Breña P, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010;99(6):883–7.
pubmed: 20163373 pmcid: 7159545 doi: 10.1111/j.1651-2227.2010.01714.x
Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012;166(8):700–6.
pubmed: 22473882 pmcid: 3394902 doi: 10.1001/archpediatrics.2011.1669
Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, Mbaga DS, Fatawou Modiyinji A, Njouom R. Systematic review and meta-analysis of the prevalence of common respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19 pandemic era. PLoS ONE. 2020;15(11): e0242302.
pubmed: 33180855 pmcid: 7660462 doi: 10.1371/journal.pone.0242302
Walton NA, Poynton MR, Gesteland PH, Maloney C, Staes C, Facelli JC. Predicting the start week of respiratory syncytial virus outbreaks using real time weather variables. BMC Med Inform Decis Mak. 2010;10:68.
pubmed: 21044325 pmcid: 2987968 doi: 10.1186/1472-6947-10-68
Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS ONE. 2014;9(2): e89186.
pubmed: 24586581 pmcid: 3935842 doi: 10.1371/journal.pone.0089186
Sharp A, Minaji M, Panagiotopoulos N, Reeves R, Charlett A, Pebody R. Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England. Influenza Other Respir Viruses. 2022;16(1):125–31.
pubmed: 34658161 doi: 10.1111/irv.12910
van Asten L, van den Wijngaard C, van Pelt W, van de Kassteele J, Meijer A, van der Hoek W, et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis. 2012;206(5):628–39.
pubmed: 22723641 doi: 10.1093/infdis/jis415
Heppe-Montero M, Gil-Prieto R, Walter S, Aleixandre-Blanquer F, De Gil MÁ. Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017. Hum Vaccin Immunother. 2022;18(1):1879.
doi: 10.1080/21645515.2021.1883379
de González DJ, Ochoa SC. Study of variability in the management of acute bronchiolitis in Spain in relation to age of patients. National multicenter study (aBREVIADo project). An Pediatr (Barc). 2010;72(1):4–18.
Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014–15. J Pediatric Infect Dis Soc. 2020;9(5):587–95.
pubmed: 31868913 doi: 10.1093/jpids/piz087
Taylor S, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK. BMJ Open. 2016;6(6): e009337.
pubmed: 27256085 pmcid: 4893852 doi: 10.1136/bmjopen-2015-009337
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015–2018. BMC Infect Dis. 2023;23(1):385.
pubmed: 37291530 pmcid: 10249572 doi: 10.1186/s12879-023-08358-x
Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341–53.
pubmed: 36372082 doi: 10.1016/S2213-2600(22)00414-3
Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345–53.
pubmed: 29365305 doi: 10.1056/NEJMoa1702090
Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171–6.
pubmed: 30625066 doi: 10.1056/NEJMra1808137
Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779–92.
pubmed: 22361396 doi: 10.1016/j.jacc.2011.09.074
World Health Organization. Life expectancy at birth, 2023. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-(years .
Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999–2018. JAMA Netw Open. 2022;5(2): e220527.
pubmed: 35226079 pmcid: 8886548 doi: 10.1001/jamanetworkopen.2022.0527
Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet. 2001;358(9291):1410–6.
pubmed: 11705487 doi: 10.1016/S0140-6736(01)06528-X

Auteurs

Mariana Haeberer (M)

Pfizer SL, Av Europa 20B, 28108, Madrid, Spain. mariana.haeberer@pfizer.com.

Robin Bruyndonckx (R)

Epidemiology and Pharmacovigilance, P95, Leuven, Belgium.

Aleksandra Polkowska-Kramek (A)

Epidemiology and Pharmacovigilance, P95, Leuven, Belgium.

Antoni Torres (A)

Clínic Barcelona Hospital, Barcelona, Spain.

Caihua Liang (C)

Pfizer Inc, New York City, USA.

Charles Nuttens (C)

Pfizer Inc, Paris, France.

Maribel Casas (M)

Epidemiology and Pharmacovigilance, P95, Leuven, Belgium.

Francesca Lemme (F)

Epidemiology and Pharmacovigilance, P95, Leuven, Belgium.

Worku Biyadgie Ewnetu (WB)

Epidemiology and Pharmacovigilance, P95, Leuven, Belgium.

Thao Mai Phuong Tran (TMP)

Epidemiology and Pharmacovigilance, P95, Leuven, Belgium.

Jessica E Atwell (JE)

Pfizer Inc, New York City, USA.

Cristina Mendez Diez (CM)

Pfizer SL, Av Europa 20B, 28108, Madrid, Spain.

Bradford D Gessner (BD)

Pfizer Inc, New York City, USA.

Elizabeth Begier (E)

Pfizer Inc, Dublin, Ireland.

Classifications MeSH